Comparison of transfusion-outcome in patients with massive bleeding receiving pathogen-reduced platelets prepared with two different technologies

Published:January 19, 2022DOI:



      Platelet concentrates(PCs) prepared with pathogen reduction technologies(PRT) are being used in routine treatment of onco-haematological patients since several years but less data are available for other pathologies.

      Study design and methods

      The aim of the study was to compare the efficacy of PCs prepared with two PRT for the treatment of patients with massive bleeding. The primary endpoint was the overall survival and in addition we analyzed the consumption of blood components in patients undergoing massive transfusion(MT). Subsequently we wanted to analyze additional known factors associated with higher in-hospital mortality.
      Retrospective analysis of two consecutive periods in which the PRT used were INTERCEPT and Mirasol, respectively.


      A total of 313 patients were included (76 % males; median age: 63 years; 160 in the INTERCEPT group and 153 in the Mirasol group).
      We found significantly higher use of platelets in the Mirasol cohort, measured either in absolute per patient number of units (3vs.4; p = 0.002) or after adjustment for the number of transfused red blood cells. The risk of death increased with age and the outof-hospital onset of bleeding, even after adjustment for one another (sub-distribution hazard ratio[sHR] 2.53, 95 % confidence interval [CI] 1.75–3.66, p < 0.001, and sHR 2.56, 95 % CI 1.82–3.60, p < 0.001, respectively).


      PRT applied to platelets did not influence MT-related mortality, but differences were found for the efficacy of the PCs treated with the different PRT which were reflected in a heightened demand for transfusion when utilizing Mirasol-treated PCs. Factors associated with higher mortality were older age and out-of-hospital bleeding.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mundt J.M.
        • Rouse L.
        • Van den Bossche J.
        • Goodrich R.P.
        Chemical and biological mechanisms of pathogen reduction technologies.
        Photochem Photobiol. 2014; 90: 957-964
        • Lin L.
        • Hanson C.V.
        • Alter H.J.
        • Jauvin V.
        • Bernard K.A.
        • Murthy K.K.
        • et al.
        Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light.
        Transfusion. 2005; 45: 580-590
        • Irsch J.
        • Lin L.
        Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood systemTM.
        Transfus Med Hemother. 2011; 38: 19-31
        • Marschner S.
        • Goodrich R.
        Pathogen reduction technology treatment of platelets, plasma and whole blood using Riboflavin and UV light.
        Transfus Med Hemother. 2011; 38: 8-18
        • Fast L.D.
        • Nevola M.
        • Tavares J.
        • Reddy H.L.
        • Goodrich R.P.
        • Marschner S.
        Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease?.
        Transfusion. 2013; 53: 373-381
        • Mintz P.D.
        • Wehrli G.
        Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products.
        Bone Marrow Transplant. 2009; 44: 205-211
        • Marschner S.
        • Fast L.D.
        • Baldwin W.M.I.I.I.
        • Slichter S.J.
        • Goodrich R.P.
        White blood cell inactivation after treatment with riboflavin and ultraviolet light.
        Transfusion. 2010; 50: 2489-2498
        • Kleinman S.
        • Stassinopoulos A.
        Transfusion-associated graft-versus-host disease reexamined: potential for improved prevention using a universally applied intervention.
        Transfusion. 2018; 58: 2545-2563
        • Castro G.
        • Merkel P.A.
        • Giclas H.E.
        • Gibula A.
        • Andersen G.E.
        • Corash L.M.
        • et al.
        Amotosalen/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease.
        Transfusion. 2018; 58: 1506-1515
        • Van Rhenen D.
        • Gulliksson H.
        • Cazenave J.P.
        • Pamphilon D.
        • Ljungman P.
        • Klüter H.
        • et al.
        Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.
        Blood. 2003; 101: 2426-2433
        • McCullough J.
        • Vesole D.H.
        • Benjamin R.J.
        • Slichter S.J.
        • Pineda A.
        • Snyder E.
        • et al.
        Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.
        Blood. 2004; 104: 1534-1541
        • Van der Meer P.F.
        • Ypma P.F.
        • van Geloven N.
        • van Hilten J.A.
        • van Wordragen-Vlaswinkel R.J.
        • Eissen O.
        • et al.
        Hemostatic efficacy of pathogen-inactivated- versus untreated- platelets: a randomized controlled trial.
        Blood. 2018; 132: 223-231
        • Rebulla P.
        • Vaglio S.
        • Beccaria F.
        • Bonfichi M.
        • Carella A.
        • Chiurazzi F.
        • et al.
        Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies.
        Transfusion. 2017; 57: 1171-1183
        • Mirasol Clinical Evaluation Study Group
        A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.
        Transfusion. 2010; 50: 2362-2375
        • Lozano M.
        • Knutson F.
        • Tardivel R.
        • Cid J.
        • Maymó R.M.
        • Löf H.
        • et al.
        A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
        Br J Haematol. 2011; 153: 393-401
        • Vamvakas E.C.
        Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system.
        Vox Sang. 2012; 102: 302-316
        • Cid J.
        • Escolar G.
        • Lozano M.
        Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials.
        Vox Sang. 2012; 103: 322-330
        • Kerkhoffs J.-L.H.
        • Van Putten W.L.J.
        • Novotny V.M.J.
        • Te Boekhorst P.A.W.
        • Schipperus M.R.
        • Zwaginga J.J.
        • et al.
        Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
        Br J Haematol. 2010; 150: 209-217
        • Garban F.
        • Guyard A.
        • Labussière H.
        • Bulabois C.E.
        • Marchand T.
        • Mounier C.
        • et al.
        Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases.
        JAMA Oncol. 2018; 4: 468-475
        • Nussbaumer W.
        • Amato M.
        • Schennach H.
        • Astl M.
        • Chen Cy
        • Lin J.-S.
        • et al.
        Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.
        Vox Sang. 2017; 112: 249-256
        • Arbaeen A.F.
        • Schubert P.
        • Serrano K.
        • Carter C.J.
        • Culibrk B.
        • Devine D.V.
        Pathogen inactivation treatment of plasma and platelet concentrates and their predicted functionality in massive transfusion protocols.
        Transfusion. 2017; 57: 1208-1217
        • Mays J.A.
        • Hess J.R.
        Modelling the effects of blood component storage lesions on the quality of haemostatic resuscitation in massive transfusion for trauma.
        Blood Transfus. 2017; 15: 153-157
        • Shaz B.H.
        • Dente C.J.
        • Harris R.S.
        • McLeod J.B.
        • Hillyer C.D.
        Transfusion management of trauma patients.
        Anesth Analg. 2009; 108: 1760-1768
        • Zatta A.J.
        • Mc Quilten Z.K.
        • Mitra B.
        • Roxby D.J.
        • Sinha R.
        • Whitehead S.
        • et al.
        Elucidating the clinical characteristics of patients captured using different definitions of massive transfusion.
        Vox Sang. 2014; 107: 60-70
        • Llau J.V.
        • Acosta F.J.
        • Escolar G.
        • Fernández-Mondéjar E.
        • Guasch E.
        • Marco P.
        • et al.
        Multidisciplinary consensus document on the management of massive haemorrhage (HEMOMAS document).
        Med Intensiva. 2015; 39 (English, Spanish, Epub 2015 Jul 29. PMID: 26233588): 483-504
        • Fine J.P.
        • Gray R.J.
        A proportional hazards model for the subdistribution of a competing risk.
        J Am Stat Assoc. 1999; 94: 496-509
        • Green L.
        • Tan J.
        • Grist C.
        Aetiology and outcome of massive transfusion in two large London teaching hospitals over a 3-year period (2012–2014).
        Transfus Med. 2017; 27: 342-347
        • Ruseckaite R.
        • McQuilten Z.K.
        • Oldroyd J.C.
        • Richter T.H.
        • Cameron P.A.
        • Isbiter J.P.
        • et al.
        Descriptive characteristics and in-hospital mortality of critically bleeding patients requiring massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry.
        Vox Sang. 2017; 112: 240-248
        • Sanz C.C.
        • Pereira A.
        Age of blood and survival after massive transfusion.
        Transfus Clin Biol. 2017; 24: 449-453
        • Mesar T.
        • Larentzakis A.
        • Dzik W.
        • Chang Y.
        • Velmahos G.
        • Yeh D.D.
        Association between ratio of fresh frozen plasma to red blood cells during massive transfusion and survival among patients without traumatic injury.
        JAMA Surg. 2017; 152: 574-580
        • Ballester-Servera C.
        • Jiménez-Marco T.
        • Morell-García D.
        • Quetglas-Oliver M.
        • Bautista-Gili A.M.
        • Girona-Llobera E.
        • et al.
        Haemostatic function measured by thromboelastography and metabolic activity of platelets treated with riboflavin and UV light.
        Blood Transfus. 2020; 18: 280-289
        • Hermida-Nogueira L.
        • Barrachina M.N.
        • Izquierdo I.
        • García-Vence M.
        • Lacerenza S.
        • Bravo S.
        • et al.
        Proteomic analysis of extracellular vesicles derived from platelet concentrates treated with Mirasol® identifies biomarkers of platelet storage lesion.
        J Proteomics. 2020; 210: 103529
        • Hess J.R.
        • Pagano M.B.
        • Barbeau J.D.
        • Johannson P.I.
        Will pathogen reduction of blood components harm more people than it helps in developed countries?.
        Transfusion. 2016; 56: 1236-1241
        • Jimenez-Marco T.
        • Garcia-Recio M.
        • Girona-Llobera E.
        Our experience in riboflavin and ultraviolet light pathogen reduction technology for platelets: from platelet production to patient care.
        Transfusion. 2018; 58: 1881-1889
        • Cazenave Jp
        • Isola H.
        • Waller C.
        • Mendel I.
        • Kientz D.
        • Laforêt M.
        • et al.
        Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period.
        Transfusion. 2011; 51: 622-629
        • Amato M.
        • Schennach H.
        • Astl M.
        • Chen Cy
        • Lin J.-S.
        • Benjamin Rj
        • et al.
        Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Care.
        Vox Sang. 2017; 112: 47-55
        • Infanti L.
        • Holbro A.
        • Passweg J.
        • Bolliger D.
        • Tsarikis D.A.
        • Merki R.
        • et al.
        Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days.
        Transfusion. 2019; 59: 3350-3361
        • Estcourt L.J.
        • Malouf R.
        • Hopewell S.
        • Trivella M.
        • Doree C.
        • Stanworth S.J.
        • et al.
        Pathogen-reduced platelets for the prevention of bleeding (Review).
        Cochrane Database Syst Rev. 2017; 7 (CD009072)
        • Van der Meer P.F.
        • de Korte D.
        Platelet additive solutions: a review of the latest developments and their clinical implications.
        Transfus Med Hemother. 2018; 45: 98-102
        • Flint A.W.J.
        • McQuilten Z.K.
        • Wood E.M.
        Massive transfusions for critical bleeding: is everything old new again?.
        Transfus Med. 2018; 28: 140-149
        • McQuilten Z.K.
        • Crighton G.
        • Brunskill S.
        • Morison J.K.
        • Richter T.H.
        • Waters N.
        • et al.
        Optimal dose, timing and ratio of blood products in massive transfusion: results from a systematic review.
        Transfus Med Rev. 2018; 32: 6-15